Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Reaffirmed by Cantor Fitzgerald

Arcturus Therapeutics (NASDAQ:ARCT)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a report released on Monday, Benzinga reports.

Several other equities analysts also recently weighed in on the stock. William Blair reiterated an “outperform” rating on shares of Arcturus Therapeutics in a research note on Thursday, May 23rd. HC Wainwright boosted their target price on shares of Arcturus Therapeutics from $60.00 to $63.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Leerink Partners initiated coverage on Arcturus Therapeutics in a research report on Monday, August 12th. They set an “outperform” rating and a $70.00 target price on the stock. Finally, Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a research report on Monday, August 12th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Arcturus Therapeutics has a consensus rating of “Buy” and a consensus target price of $71.40.

Arcturus Therapeutics Stock Performance

NASDAQ ARCT opened at $19.76 on Monday. The company has a market capitalization of $532.14 million, a PE ratio of -5.05 and a beta of 2.60. Arcturus Therapeutics has a 52-week low of $17.52 and a 52-week high of $45.00. The company has a 50-day simple moving average of $21.44 and a 200 day simple moving average of $28.25.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. The company had revenue of $49.86 million for the quarter, compared to analysts’ expectations of $21.00 million. During the same quarter in the previous year, the firm posted ($1.98) EPS. As a group, analysts forecast that Arcturus Therapeutics will post -2.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Arcturus Therapeutics

Large investors have recently added to or reduced their stakes in the business. Nordea Investment Management AB purchased a new position in shares of Arcturus Therapeutics during the first quarter worth about $1,846,000. Sumitomo Mitsui Trust Holdings Inc. raised its position in Arcturus Therapeutics by 22.4% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company’s stock worth $38,061,000 after purchasing an additional 286,546 shares during the period. Campbell & CO Investment Adviser LLC bought a new stake in Arcturus Therapeutics in the fourth quarter worth $927,000. Hennion & Walsh Asset Management Inc. boosted its position in Arcturus Therapeutics by 2.5% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 31,930 shares of the biotechnology company’s stock valued at $1,078,000 after buying an additional 778 shares during the period. Finally, Wellington Management Group LLP grew its stake in shares of Arcturus Therapeutics by 40.3% during the fourth quarter. Wellington Management Group LLP now owns 60,841 shares of the biotechnology company’s stock valued at $1,918,000 after buying an additional 17,491 shares during the last quarter. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.